PDE5A and benign prostatic hyperplasia: Pharmacotherapies targeting smooth muscle tone, notably α1A-adrenoreceptor antagonists (alpha blockers)4 and Phosphodiesterase-5 inhibitors (PDE5-Is), are currently used for the treatment of BPH and alleviation of LUTS.